
Thomas Wiegel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7833393/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. World Journal of Urology, 2021, 39, 65-72.	2.2	2
2	Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. Radiotherapy and Oncology, 2021, 154, 255-259.	0.6	6
3	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	1.9	1,545
4	Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology, 2021, 147, 235-242.	2.5	9
5	Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1273-1274.	2.5	0
6	Options for Curative Treatment of Localized Prostate Cancer. Deutsches Ärzteblatt International, 2021, 118, .	0.9	7
7	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 150-169.	5.4	23
8	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology, 2021, 80, 531-545.	1.9	21
9	Postoperative radiotherapy in prostate cancer. Lancet, The, 2021, 397, 1623.	13.7	3
10	Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy. Frontiers in Oncology, 2021, 11, 665304.	2.8	7
11	Re: Timing of Radiotherapy After Radical Prostatectomy (RadicalS-RT): A Randomised, Controlled Phase 3 Trial. European Urology, 2021, 80, 117.	1.9	1
12	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.7	2
13	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	2.0	16
14	Timing of ADT in Radiotherapy of Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2315-2316.	1.6	1
15	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. Journal of Clinical Oncology, 2021, 39, 2284-2293.	1.6	54
16	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. Frontiers in Oncology, 2021, 11, 723536.	2.8	5
17	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. Journal of Nuclear Medicine, 2021, 62, jnumed.120.249029.	5.0	15
18	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus, 2020, 6, 231-234.	3.1	131

#	Article	IF	CITATIONS
19	Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732–9. European Urology, 2020, 77, e60-e61.	1.9	1
20	Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614–27. European Urology, 2020, 78, e116-e117.	1.9	0
21	Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?. International Journal of Radiation Oncology Biology Physics, 2020, 108, 903-904.	0.8	Ο
22	Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer. Journal of Clinical Oncology, 2020, 38, 1746-1746.	1.6	1
23	Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265–7. European Urology, 2019, 76, e148-e149.	1.9	Ο
24	The impact of <scp>prostateâ€specific antigen</scp> persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary NO prostate cancer. BJU International, 2019, 124, 785-791.	2.5	20
25	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. European Urology, 2019, 76, 179-186.	1.9	15
26	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. European Urology, 2019, 76, 443-449.	1.9	14
27	The role of radiotherapy in localised and locally advanced prostate cancer. Asian Journal of Urology, 2019, 6, 153-161.	1.2	14
28	Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 344-349.	3.9	17
29	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 619-626.	2.0	26
30	Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 325-332.	2.0	5
31	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	1.9	488
32	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	1.9	36
33	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	1.9	60
34	Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncológica, 2018, 57, 362-367.	1.8	28
35	Rituximab With Involved Field Irradiation for Earlyâ€stage Nodal Follicular Lymphoma. HemaSphere, 2018, 2, e160.	2.7	33
36	Optimizing radiotherapy for intermediate-risk localized disease. Nature Reviews Urology, 2018, 15, 470-471.	3.8	2

#	Article	IF	CITATIONS
37	Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 692-699.	2.0	19
38	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 869-885.	1.9	182
39	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	1.9	77
40	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2017, 71, 618-629.	1.9	2,497
41	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. European Urology, 2017, 71, 630-642.	1.9	1,215
42	Postoperative Irradiation: Immediate or Early Delayed?. , 2017, , 231-250.		0
43	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in ≥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 333-340.	0.8	16
44	Quality assessment in prostate cancer centers certified by the German Cancer Society. World Journal of Urology, 2016, 34, 665-672.	2.2	23
45	The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Radiotherapy and Oncology, 2016, 118, 131-135.	0.6	16
46	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology, 2016, 69, 728-733.	1.9	102
47	Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor ofÂClinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial. International Journal of Radiation Oncology Biology Physics, 2015, 91, 288-294.	0.8	77
48	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. Critical Reviews in Oncology/Hematology, 2015, 95, 133-143.	4.4	23
49	Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin – A multicenter study. Radiotherapy and Oncology, 2015, 116, 119-124.	0.6	16
50	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. European Urology, 2015, 67, 904-912.	1.9	18
51	Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. European Urology, 2015, 68, 775-776.	1.9	1
52	PREFEREnce-based Randomized Evaluation of Treatment Modalities in Low or Early Intermediate-risk Prostate Cancer. European Urology, 2015, 67, 1-2.	1.9	10
53	Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial. European Urology, 2014, 66, 243-250.	1.9	354
54	Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy. Strahlentherapie Und Onkologie, 2014, 190, 727-731.	2.0	22

#	Article	IF	CITATIONS
55	Early Salvage Radiotherapy Following Radical Prostatectomy. European Urology, 2014, 65, 1034-1043.	1.9	171
56	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European Urology, 2014, 65, 467-479.	1.9	1,304
57	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013. European Urology, 2014, 65, 124-137.	1.9	1,613
58	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2014, 66, 479-486.	1.9	121
59	Randomized Trials for Adjuvant Radiotherapy. Medical Radiology, 2014, , 231-242.	0.1	Ο
60	Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results. World Journal of Urology, 2013, 31, 423-428.	2.2	13
61	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. International Journal of Radiation Oncology Biology Physics, 2013, 87, 960-967.	0.8	16
62	Interdisciplinary decision making in prostate cancer therapy – 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin. BMC Medical Informatics and Decision Making, 2013, 13, 83.	3.0	9
63	Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162.	1.2	137
64	Phase 3 Study of Adjuvant Radiotherapy Versus Wait and See in pT3 Prostate Cancer: Impact of Pathology Review on Analysis. European Urology, 2013, 64, 193-198.	1.9	38
65	Adjuvant radiotherapy or early salvage radiotherapy in pT3R0 or pT3R1 prostate cancer. Current Opinion in Urology, 2013, 23, 360-365.	1.8	5
66	Radiotherapy in the management of prostate cancer after radical prostatectomy. Future Oncology, 2013, 9, 669-679.	2.4	5
67	Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. European Urology, 2012, 62, 472-487.	1.9	157
68	Salvage radiotherapy after prostatectomy – What is the best time to treat?. Radiotherapy and Oncology, 2012, 103, 239-243.	0.6	56
69	Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2012, 61, 112-127.	1.9	224
70	Postoperative Irradiation: Immediate or Early Delayed?. , 2012, , 173-189.		0
71	Prostate. Medical Radiology, 2011, , 949-1025.	0.1	0
72	EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. European Urology, 2011, 59, 61-71.	1.9	1,299

#	Article	IF	CITATIONS
73	Dose Escalation for Patients with Decreasing PSA during Radiotherapy for Elevated PSA after Radical Prostatectomy Improves Biochemical Progression-Free Survival. Strahlentherapie Und Onkologie, 2011, 187, 467-472.	2.0	36
74	Letter to the Editor on: A. Siegmann et al. Dose Escalation for Patients with Decreasing PSA during Radiotherapy for Elevated PSA after Radical Prostatectomy Improves Biochemical ProgressionFree Survival. Results of a Retrospective Study. Strahlentherapie Und Onkologie, 2011, 187, 763-764.	2.0	1
75	The German S3 Guideline Prostate Cancer. Strahlentherapie Und Onkologie, 2010, 186, 531-534.	2.0	26
76	Radiotherapy and Prostate Cancer: Quo Vadis?. European Urology Supplements, 2010, 9, 394-400.	0.1	1
77	Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95. Journal of Clinical Oncology, 2009, 27, 2924-2930.	1.6	779
78	Postoperative Radiotherapy for Advanced Prostate Cancer. Strahlentherapie Und Onkologie, 2009, 185, 485-487.	2.0	5
79	Achieving an Undetectable PSA After Radiotherapy for Biochemical Progression After Radical Prostatectomy Is an Independent Predictor of Biochemical Outcome—Results of a Retrospective Study. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1009-1016.	0.8	127
80	Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer. European Journal of Cancer, 2009, 45, 148-157.	2.8	10
81	Adjuvant radiotherapy after radical prostatectomy. European Journal of Cancer, Supplement, 2007, 5, 171-176.	2.2	4
82	Adjuvant Radiotherapy after Radical Prostatectomy: Indications, Results and Side Effects. Urologia Internationalis, 2007, 78, 193-197.	1.3	24
83	Percutaneous radiotherapy for low-risk prostate cancer: options for 2007. World Journal of Urology, 2007, 25, 53-57.	2.2	6
84	Salvage Radiotherapy in Patients with Persisting Prostate-Specific Antigen after Radical Prostatectomy for Prostate Cancer. Oncology, 2003, 65, 18-23.	1.9	5
85	Radiation Therapy of Para-Aortic Lymph Nodes in Cancer of the Uterine Cervix. Acta Oncológica, 1993, 32, 63-67.	1.8	12
86	Prostatakarzinom: PREFERE-Studie – Eine Standortbestimmung. , 0, , .		0